RNA Targeting Small Molecule Drug Discovery

Global RNA Targeting Small Molecule Drug Discovery Market to Reach US$5.3 Billion by 2030

The global market for RNA Targeting Small Molecule Drug Discovery estimated at US$1.8 Billion in the year 2024, is expected to reach US$5.3 Billion by 2030, growing at a CAGR of 19.9% over the analysis period 2024-2030. Cancer, one of the segments analyzed in the report, is expected to record a 18.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Infectious Diseases segment is estimated at 20.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$471.1 Million While China is Forecast to Grow at 19.0% CAGR

The RNA Targeting Small Molecule Drug Discovery market in the U.S. is estimated at US$471.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$823.1 Million by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.9% and 17.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global RNA Targeting Small Molecule Drug Discovery Market - Key Trends & Drivers Summarized

Why Is RNA Targeting Emerging As A Revolutionary Approach In Drug Discovery?

The field of drug discovery has witnessed a paradigm shift with the growing focus on RNA-targeting small molecules, a breakthrough approach that extends beyond traditional protein-based therapeutics. RNA plays a critical role in gene expression and regulation, making it an attractive target for treating a wide array of diseases, including cancer, neurodegenerative disorders, and viral infections. Advances in structural biology and high-throughput screening techniques have enabled the identification of small molecules that can selectively bind to RNA structures, offering novel therapeutic avenues. The ability of small molecules to modulate RNA function, either by stabilizing secondary structures or interfering with RNA-protein interactions, has opened up possibilities for treating previously undruggable targets. Additionally, the development of computational modeling and AI-driven drug screening is accelerating the discovery of potent RNA-targeting compounds. The integration of RNA-focused libraries and fragment-based drug discovery approaches is further enhancing the precision and efficiency of this emerging domain, positioning RNA-targeting therapeutics as a transformative force in modern medicine.

How Are Recent Breakthroughs In RNA Biology Driving Market Expansion?

Recent advances in RNA biology have significantly bolstered the development of RNA-targeting small molecule drugs, enabling more precise intervention in disease pathways. The discovery of functional RNA structures, such as riboswitches, long non-coding RNAs (lncRNAs), and microRNAs, has expanded the scope of therapeutic targets. Researchers are now leveraging RNA structural mapping techniques, including cryo-electron microscopy (cryo-EM) and NMR spectroscopy, to identify highly specific druggable RNA motifs. Additionally, the success of RNA-based therapeutics, such as mRNA vaccines and antisense oligonucleotides, has underscored the immense potential of RNA as a therapeutic target. Companies are increasingly investing in next-generation RNA-targeting libraries, enabling more effective screening and optimization of small-molecule candidates. Furthermore, the emergence of RNA degrader technologies, such as RIBOTACs (ribonuclease-targeting chimeras), is providing a novel strategy for selectively degrading disease-associated RNA sequences. These breakthroughs are accelerating the expansion of RNA-focused drug discovery, attracting significant investment and fostering strategic collaborations between biotech firms and pharmaceutical giants.

What Is Fueling The Interest Of Pharma & Biotech Companies In RNA-Targeted Therapies?

The growing interest of pharmaceutical and biotech companies in RNA-targeting small molecules is driven by the urgent need for innovative therapeutics that address unmet medical needs. Traditional drug development approaches targeting proteins have reached limitations, particularly in diseases with complex genetic underpinnings. RNA-targeting molecules offer an alternative strategy by intervening at the transcriptional level, potentially preventing disease progression before harmful proteins are even synthesized. Moreover, RNA’s inherent structural plasticity allows for more diverse targeting opportunities compared to conventional protein inhibitors. With regulatory bodies granting accelerated approvals for novel RNA-targeting therapeutics, major pharma players are actively expanding their RNA-focused pipelines. Strategic collaborations, mergers, and acquisitions are on the rise, with companies investing heavily in proprietary RNA-targeting platforms. The ability of small molecules to penetrate cells more efficiently than larger RNA-based drugs is further driving the commercial appeal of this approach. As funding for RNA research continues to grow, the pharmaceutical sector is witnessing a surge in RNA-targeting programs aimed at addressing rare genetic disorders, oncology, and infectious diseases.

What Are The Key Growth Drivers Propelling The Market Forward?

The growth in the RNA-targeting small molecule drug discovery market is driven by several factors, including technological advancements in RNA structural analysis, the rising prevalence of complex diseases, and the increasing demand for innovative therapeutics. The expansion of high-throughput screening techniques, coupled with AI-powered drug discovery platforms, is significantly accelerating the identification of RNA-binding molecules. Additionally, the success of RNA-based therapies, such as mRNA vaccines, has strengthened investor confidence in RNA-targeted approaches. The growing recognition of RNA as a critical regulatory element in disease progression is fueling the development of new therapeutic strategies targeting non-coding RNAs and structured RNA elements. The pharmaceutical industry`s push towards personalized medicine, coupled with a surge in biotech startups focused on RNA therapeutics, is further amplifying market growth. As RNA-targeting strategies continue to evolve, the market is expected to witness increased adoption, backed by strategic collaborations, regulatory support, and breakthrough innovations in RNA-focused drug development.

SCOPE OF STUDY:

The report analyzes the RNA Targeting Small Molecule Drug Discovery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others); End-Use (Pharma & Biopharma Companies, Academic & Research Institutes, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

• Accent Therapeutics Inc.
• Alnylam Pharmaceuticals Inc.
• Amgen Inc.
• Anima Biotech Inc.
• Arbutus Biopharma Corporation
• Arrakis Therapeutics
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• Dicerna Pharmaceuticals Inc.
• Eli Lilly and Company
• Epics Therapeutics
• Evotec SE
• Expansion Therapeutics
• F. Hoffmann-La Roche Ltd
• H3 Biomedicine Inc.
• Ionis Pharmaceuticals Inc.
• Merck & Co., Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.